Jatinder Dhaliwal, a director and 10% owner of Virpax Pharmaceuticals, filed an initial statement of beneficial ownership with the SEC, as per Form 3 requirements. The filing, dated July 5, 2024, indicates that Dhaliwal does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Vinay Shah on behalf of Dhaliwal, was completed on July 9, 2024. This standard disclosure is part of the regulatory compliance for individuals in significant positions within publicly traded companies, ensuring transparency in ownership stakes.

Jatinder Dhaliwal, a director and 10% owner of Virpax Pharmaceuticals, filed an initial statement of beneficial ownership with the SEC, as per Form 3 requirements. The filing, dated July 5, 2024, indicates that Dhaliwal does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Vinay Shah on behalf of Dhaliwal, was completed on July 9, 2024. This standard disclosure is part of the regulatory compliance for individuals in significant positions within publicly traded companies, ensuring transparency in ownership stakes.